Management ChangeJun 16, 2026, 04:37 PM
Travere Therapeutics CRO Rote to Retire; CMO Inrig Named EVP, Head of R&D
AI Summary
Travere Therapeutics announced that Dr. William Rote, Chief Research Officer, will retire effective February 17, 2027. Dr. Rote will continue in his role until his retirement date to ensure a smooth transition of responsibilities. His duties are expected to be assumed by Dr. Jula Inrig, the current Chief Medical Officer, who will also be named Executive Vice President, Head of Research & Development, effective July 1, 2026. The company also plans to engage Dr. Rote in a consulting arrangement post-retirement.
Key Highlights
- Dr. William Rote, Chief Research Officer, announced his retirement from Travere Therapeutics.
- Dr. Rote's retirement is effective February 17, 2027, marking his 10-year anniversary with the company.
- He will continue in his current position until the retirement date to assist with the transition.
- Dr. Jula Inrig, Chief Medical Officer, will assume Dr. Rote's responsibilities.
- Effective July 1, 2026, Dr. Inrig will be named Executive Vice President, Head of Research & Development and Chief Medical Officer.
- Travere Therapeutics expects to enter into a consulting arrangement with Dr. Rote after his retirement.
Price Impact
More from TVTX